Why Is Telomir Pharmaceuticals Stock (TELO) Up 150% Today?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The big news today is Telomir-1's ability to reverse epigenetic gene silencing in aggressive human prostate cancer cells. This revelation comes from a study of these cells in mice. Telomir Pharmaceuticals noted that Telomir-1 outperformed Paclitaxel and Rapamycin, two cancer treatments, in this study.
Telomir Pharmaceuticals CEO Erez Aminov said, 'This study provides novel and direct molecular evidence of Telomir-1's ability to reprogram cancer epigenetics. By potentially restoring the function of key tumor suppressor genes like STAT1, we're not just slowing tumor growth-we're turning the immune system back on.'
Telomir Pharmaceuticals Stock Movement Today
Telomir Pharmaceuticals stock was up 152.07% on Friday, extending a 5.22% rally from yesterday. Even so, the shares have fallen 70.63% year to date and 67.73% over the past 12 months. Today's rally came with heavy trading, as some 57 million shares changed hands, compared to a three-month daily average of about 381,000 units.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Wegovy maker Novo's profit warning triggers $70 billion share rout
By Jacob Gronholt-Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year. "The magnitude of the guidance cut is a shocker," Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than "compounded" copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the U.S., both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen. At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market. "The stock has gone from being a market darling to one of its biggest letdowns," said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. "The biggest concern is the illegal channel siphoning away market share - something that's hard to quantify. Rebuilding trust will take time." NEW CEO AN INSIDER Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7. He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. "We need to increase the sense of urgency and execute differently," Doustdar told investors and analysts on a call. "The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear." Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. In May, Novo said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. "Unfortunately, our latest market research indicates that has not happened," Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more U.S. patients are still using compounded GLP-1s, he said. Novo has stepped up its dialogue with the U.S. FDA to limit unlawful compounding of its drugs, the head of U.S. operations David Moore added on the call. "Compounding continues to be an issue that we have to address," Moore said. ($1 = 0.8672 euros) Sign in to access your portfolio
Axios
2 hours ago
- Axios
Trump's tax bill blows $1.2B hole in Colorado budget
President Trump's "big, beautiful bill" will create a $1.2 billion hole in Colorado's current state budget, according to a new pair of economic forecasts. Why it matters: The financial hit is unprecedented and forces lawmakers to consider raising taxes or cutting key services. "We don't have the money to pay our bills, so we need to do something," Mark Ferrandino, the governor's budget director, told top lawmakers in a presentation Wednesday. State of play: Unlike most states, Colorado's tax policies are intricately linked to federal law, making the state more susceptible to changes made by Congress compared to peers. By the numbers: The federal spending bill, also known as H.R. 1, will lower the state's individual income tax collections by $376 million and reduce corporate taxes by $825 million in the current fiscal year, the governor's office estimated. Other federal tax changes, such as no tax on tips and interest on car loans, will cost millions more in lost revenue, legislative analysts noted. What's next: To address the deficit in the $44 billion budget, Colorado lawmakers are preparing to return to the state Capitol for a special legislative session as early as mid-August. The options to address the budget hole include tapping into the state's reserve fund, cutting back on safety net programs such as Medicaid and raising taxes and fees. What they're saying:"We have difficult decisions ahead and will do everything we can to minimize the harm, but there's no avoiding the fact that these cuts will hurt Colorado families," Senate President James Coleman (D-Denver) said in a statement. The other side: Republicans called the legislative hearing "political theatrics" and blamed the Democratic majority's overspending in prior years for the current budget crisis.
Newsweek
4 hours ago
- Newsweek
US Visa Interviews To Change From September: What To Know
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Department of State has announced major changes to its visa interview policies that are set to take effect from September 2. Under the revised rules, most nonimmigrant visa applicants would be required to attend an in-person interview, ending broad exemptions that had been in place in recent years. Why It Matters U.S. consulates are set to adopt a much more limited version of the nonimmigrant visa interview waiver program, according to a State Department announcement. Under the revised policy, almost all applicants would be required to attend an in-person interview, with limited exceptions for most diplomatic visa applicants and certain B-1/B-2 visa holders. Notably, the new rules also mandate interviews for applicants under 14 and over 79 years of age, reversing the long-standing exemption for these age groups. The move is expected to affect thousands of travelers, students and business professionals seeking entry to the United States and underscores the State Department's renewed emphasis on in-person vetting and security checks in visa processing. A sign at the State Department in Washington, D.C. A sign at the State Department in Washington, D.C. Charles Dharapak/AP What To Know Several categories of applicants would remain eligible for an interview waiver under the revised rules. These include individuals applying for diplomatic and official visas, such as A-1, A-2, C-3 (excluding personal staff), G-1 to G-4, NATO-1 through NATO-6, and TECRO E-1. The waiver would also apply to those renewing a full-validity B-1, B-2 or B1/B2 visas or a Border Crossing Card/Foil for Mexican nationals—provided the renewal occurs within 12 months of the previous visa's expiration and the applicant was at least 18 years old when the prior visa was issued. Applicants seeking an interview waiver based on visa renewal must meet additional eligibility criteria. They must apply from their country of nationality or residence, have no history of visa refusal unless it was later overcome or waived, and must not have any apparent or potential grounds of ineligibility. Even if applicants meet these conditions, U.S. consular officers reserve the right to request an in-person interview on a case-by-case basis. This policy supersedes the previous interview waiver guidelines announced on February 18 and marks a shift toward tighter screening as global travel returns to pre-pandemic levels. What People Are Saying AK Poku Law, an immigration law firm in Virginia, wrote on X: "Due to this change, applicants should expect longer wait times and processing backlogs at U.S. embassies and consulates." Reddy Neumann Brown PC, an immigration law firm in Texas, wrote on X: "Long-standing exemptions are being rolled back, appointment demand is expected to surge, and delays could stretch for months." What Happens Next The changes are set to come into effect in September. The State Department is urging applicants to check the official website of the U.S. Embassy or consulate where they plan to apply, as procedures and processing times may vary by location.
